Disease · HP_0040270
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Orlistat vs Placebo: serious adverse events | 0 of 100 | 2 of 100 | 200 | NCT00001723 | Trial comparisons |
| ACZ885 150mg vs Placebo: serious adverse events | 25 of 95 | 14 of 94 | 189 | NCT00995930 | Trial comparisons |
| Group A (Exenatide) vs Group B (Placebo): serious adverse events | 0 of 73 | 0 of 79 | 152 | NCT00500370 | Trial comparisons |
| Group A (Exenatide) vs Group B (Placebo): Incidence of Patients That Demonstrate Overt Signs of Diabetes Mellitus Diagnosis | 3 of 65 | 2 of 65 | 130 | NCT00500370 | Trial comparisons |
| Salsalate Therapy vs Placebo: serious adverse events | 0 of 34 | 0 of 36 | 70 | NCT00330733 | Trial comparisons |
| Pioglitazone vs Pioglitazone + Exercise Training: serious adverse events | 0 of 20 | 0 of 19 | 39 | NCT00639457 | Trial comparisons |
| Group A (Exenatide) vs Group B (Placebo): Incidence of Patients That Demonstrate Normalization of Impaired Fasting Glucose (IFG) and/or Impaired Glucose Tolerance (IGT) | 13 of 17 | 9 of 16 | 33 | NCT00500370 | Trial comparisons |
| Fenofibrate 145mg PO QD vs Fenofibrate 145 mg PO QD and Pioglitazone 45 mg PO QD: serious adverse events | 0 of 15 | 0 of 12 | 27 | NCT00470262 | Trial comparisons |
| Sitagliptin vs Placebo: deaths from any cause | 0 of 13 | 0 of 13 | 26 | NCT01879228 | Trial comparisons |
| Sitagliptin vs Placebo: serious adverse events | 0 of 13 | 0 of 13 | 26 | NCT01879228 | Trial comparisons |
| Exenatide vs Control: serious adverse events | 0 of 11 | 0 of 11 | 22 | NCT00886626 | Trial comparisons |
| Active Arm (Rosiglitazone) vs Inactive Arm (Placebo): serious adverse events | 0 of 12 | 0 of 9 | 21 | NCT00413335 | Trial comparisons |
| Treatment vs Placebo: serious adverse events | 0 of 9 | 0 of 8 | 17 | NCT00402194 | Trial comparisons |
| Relacorilant (RW Phase) vs Placebo (RW Phase): Number of Patients With Any Increase or Modification in Diabetes Medication During the RW Phase | 1 of 7 | 0 of 8 | 15 | NCT03697109 | Trial comparisons |
| Sitagliptin, Then Placebo vs Placebo, Then Sitagliptin: serious adverse events | 0 of 5 | 0 of 5 | 10 | NCT01488279 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0040270/comparisons